Amicus Therapeutics, Inc. $FOLD Shares Bought by Stephens Investment Management Group LLC

Key Points

• Stephens Investment Management Group LLC increased its position in Amicus Therapeutics by 35.9%, acquiring an additional 220,173 shares during the second quarter.
• The biopharmaceutical company's stock is currently valued at $8.55 per share, with a market cap of $2.64 billion and a consensus price target of $15.88.
• Multiple research firms have given varying ratings on Amicus Therapeutics, with one analyst rating it as a Strong Buy and others issuing ratings ranging from Buy to Sell.

Stephens Investment Management Group LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 35.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 832,643 shares of the biopharmaceutical company's stock after acquiring an additional 220,173 shares during the period. Stephens Investment Management Group LLC owned approximately 0.27% of Amicus Therapeutics worth $4,771,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Diversified Trust Co increased its holdings in shares of Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after purchasing an additional 1,784 shares in the last quarter. Tempus Wealth Planning LLC increased its holdings in Amicus Therapeutics by 7.2% during the 1st quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock valued at $241,000 after acquiring an additional 1,990 shares in the last quarter. Stephens Inc. AR increased its holdings in Amicus Therapeutics by 27.4% during the 1st quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company's stock valued at $111,000 after acquiring an additional 2,938 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares in the last quarter. Finally, Strs Ohio purchased a new position in Amicus Therapeutics during the 1st quarter valued at about $30,000.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $8.55 on Thursday. The company has a market cap of $2.64 billion, a PE ratio of -71.24 and a beta of 0.56. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The company has a 50-day simple moving average of $7.97 and a 200-day simple moving average of $6.91.

Wall Street Analyst Weigh In

Several research firms have weighed in on FOLD. Weiss Ratings restated a "sell (e+)" rating on shares of Amicus Therapeutics in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, October 18th. Zacks Research upgraded shares of Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, Needham & Company LLC upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price for the company in a report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.